Find Clinical Trial
Study assessing the glucose-lowering efficacy and safety of luseogliflozin on top of metformin in Caucasian patients with type 2 diabetes mellitus
← Back
| Study Phase |
Phase 3 |
| Therapeutic Area |
Metabolism |
| Indication | Diabetes - Type II |
| Sponsor | JSC Servier (Russia) |
| Active substance/ Medical device |
Luseogliflozin |
| Active Substance Code | Luseogliflozin |
| Protocol Code | CL3-LUSEO-001 |
| ISRCTN Code | ISRCTN39549850 |
Documents and links
| Results are not yet available. |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2025 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
